

# FDA approves velsipity for moderate-to-severe ulcerative colitis in adults

October 18 2023, by Lori Solomon

---



The U.S. Food and Drug Administration has approved [Velsipity](#)

(etrasimod) for adults with moderately to severely active ulcerative colitis (UC).

The approval was based on results from the ELEVATE UC phase 3 registrational program (ELEVATE UC 52 and ELEVATE UC 12) that included UC [patients](#) who had previously failed or were intolerant to at least one conventional, biologic, or Janus kinase inhibitor therapy.

In ELEVATE UC 52, 27.0% of patients receiving Velsipity achieved clinical remission versus 7.0% of patients receiving [placebo](#) at week 12, and at week 52, clinical remission was achieved by 32.0 and 7.0%, respectively.

In ELEVATE UC 12, 26.0% of patients receiving Velsipity achieved clinical remission versus 15.0% of patients receiving placebo. At week 12, all key secondary efficacy end points were met, including endoscopic improvement and mucosal healing.

The selective sphingosine-1-phosphate receptor modulator was approved at a 2mg recommended dose. The safety of Velsipity was consistent with previous studies, with the most common adverse reactions being headache, elevated liver tests, and dizziness (incidence  $\geq 5\%$ ).

"Velsipity provides [adults](#) living with moderately-to-severely active UC the opportunity to achieve steroid-free remission with an oral, once-daily pill that has a favorable benefit-risk profile," Angela Hwang, Pfizer chief commercial officer and president of global biopharmaceuticals business, said in a statement.

Approval of Velsipity was granted to Pfizer.

**More information:** [More Information](#)

Copyright © 2023 [HealthDay](#). All rights reserved.

Citation: FDA approves velsipity for moderate-to-severe ulcerative colitis in adults (2023, October 18) retrieved 29 April 2024 from <https://medicalxpress.com/news/2023-10-fda-velsipity-moderate-to-severe-ulcerative-colitis.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.